Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The study design is a phase II interventional trial for women with biopsy proven high-grade
cervical dysplasia. The study is an open label study and randomized. The study will have two
arms. Patients will be randomized to both arms.